Hahn testifies on Covid-19 response, says FDA on target to hit user fee goals

Michael Mezher

FDA commissioner Stephen Hahn on Tuesday testified before the House Energy and Commerce Committee on his agency’s response to the coronavirus disease (Covid-19) pandemic. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hahn testifies on Covid-19 response, says FDA on target to hit user fee goals

Michael Mezher

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Hahn tes­ti­fies on Covid-19 re­sponse, says FDA on tar­get to hit user fee goals

Michael Mezher

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Hahn testifies on Covid-19 response, says FDA on target to hit user fee goals

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.